108384
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
个案报道：碘 125 粒子植入与异体自然杀伤细胞免疫治疗医治肝移植后肝癌复发一例
Authors Xie S, Wu Z, Zhou L, Liang Y, Wang X, Niu L, Xu K, Chen J, Zhang M
Received 28 February 2018
Accepted for publication 10 August 2018
Published 25 October 2018 Volume 2018:11 Pages 7345—7352
DOI https://doi.org/10.2147/OTT.S166962
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 4
Editor who approved publication: Dr Arseniy Yuzhalin
摘要：肝移植（LT）是治疗晚期肝细胞癌（HCC）的最佳方案。LT 后需要服用免疫抑制药物对抗排斥反应，而免疫抑制又正好是肝癌复发的诱因。因此 HCC 患者在 LT 后存在着肝癌复发的风险。综上所述，我们报道一名 LT 后 HCC 复发的 29 岁男子。该男子在接受化疗（剂量：45 Gy）后病情并无改善。我们对此采用碘 125 粒子植入联合异体自然杀伤细胞免疫治疗。疗效评估由肝功能，免疫功能，循环肿瘤细胞和 CT 图像扫描判断。临床效果显示患者接受治疗后肝功能回复，免疫功能增强，肿瘤较治疗前缩小。这是首次采用碘 125 粒子植入联合异体自然杀伤细胞免疫治疗的报道，该疗法对 LT 后 HCC 复发这一临床难题有一定启示作用。
Keywords: hepatic carcinoma, iodine seeds implantation, natural killer cells, allogenic
